|Advanced Health & Life Extension||
Oral Proteolytic Enzyme References
These references apply to the article on Oral Proteolytic Enzymes .
1. Brendel R, Beiler JM, Martin GJ. American Journal of Pharmacology 1956;128:172.
2. Martin GJ, Brendal R, Beiler JM. Uptake of labelled chymotrypsin across the GI. American Journal of Pharmacology 1957;129:194-197.
3. Ambrus JC, Lassman HB, Marchijj DE. Absorption of exogenous and endogenous proteolytic enzymes. Clinical Pharmacology and Therapeutics 1967;8(3):362-367.
4. Vakians A. Further studies on the absorption of chymotrypsin. Clinical Pharmacology and Therapeutics 1964:5(6):712-715.
5. Miller J, Opher A. Increased proteolytic activity of human blood serum after oral administration of bromelain. Exp Med Surg 1964;22:277.
6. Innerfield I, Wernick T. Plasma anti-thrombin alterations following oral papain. Proc Soc Ext Biol Med July 1961;107:505-506.
7. Miller J. Absorption of proteolytic enzymes from the gastrointestinal tract. Clinical Medicine October 1968;75:35-40.
8. Ito C. Anti-inflammatory actions of proteases, bromelain, trypsin and their mixed preparations. Folia Pharmacol JPN 1979;75:227.
9. Kabacoff B, Wohlman A, et al. Absorption of chymotrypsin from the intestinal tract. Nature 1963;199:815.
10. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol . 1988;22:191-203
11. Deitrick RE. Oral Proteolytic Enzymes in the treatment of athletic injuries: a double-blind study. Pa Med.1965;68:35-37
12. Blonstein JL. Control of swelling in boxing injuries. Practitioner. 1969;203:206.
13. Baumuller M. The application of hydrolytic enzymes in blunt wounds to the soft tissue and distortion of the ankle joint: a double-blind clinical trial [translated from German]. Allgemeinmedizin. 1990;19:178-182.
14. Zuschlag JM. Double-blind clinical study using certain pproteolytic enzyme mixtures in karate fighters. Working paper. Mucos Pharma GmbH (Germany). 1988;1-5.
15. Rathgeber WF. The use of proteolytic enzymes (Chymoral) in sporting injuries. S Afr Med J. 1971;45:181-183.
16. Deitrick RE. Oral Proteolytic Enzymes in the treatment of athletic injuries: a double-blind study. Pa Med. 1965;68:35-37
17. Smyth RD, Brennan R, Martin GJ. Studies establishing the absorption of bromelains (Proteolytic enzymes) from the gastrointestinal tract. Exp Med Surg. 1964;22: 46-59.
18. Miller JM, Ginseberg M, McElfatrick GC, et al. The administration of bromelain orally in the treatment of inflammation and edema. Exp Med Surg. 1964;22:293-299.
19. Castell JV, Friedrich G, Kuhn CS, et al. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol. 1997;273:G139-G146.
20. Billigmann VP. Enzyme therapy-an alternative in treatment of herpes zoster. A controlled study of 192 patients [translated from German]. Fortschr Med. 1995;113:43-48.
21. Kleine MW, Stauder GM, Beese EW. The intestinal absorption of orally administered hydrolytic enzymes and their effects in the treatment of acute herpes zoster as compared with those of oral acyclovir therapy. Phytomedicine. 1995;2:7-15.
22. Baumuller M. The application of hydrolytic enzymes in blunt wounds to the soft tissue and distortion of the ankle joint: a double-blind clinical trial [translated from German]. Allgemeinmedizin. 1990;19:178-182.
23. Zuschlag JM. Double-blind clinical study using certain proteolytic enzyme mixtures in karate fighters. Working paper. Mucos Pharma GmbH (Germany). 1988;1-5.
24. Rathgeber WF. The use of proteolytic enzymes (Chymoral) in sporting injuries. S Afr Med J. 1971;45:181-183.
25. Deitrick RE. Oral Proteolytic Enzymes in the treatment of athletic injuries: a double-blind study. Pa Med.1965;68:35-37.
26. Shaw PC. The use of a trypsin-chymotrypsin formulation in fractures of the hand. Br J Clin Pract. 1969;23:25-26.
27. Kleine MW, Pabst H. The effect of an oral enzyme therapy on experimentally produced hematomas [translated from German]. Forum des Prakt und Allgemeinarztes. 1988;27:42, 45-46, 48.
28. Rahn HD. Efficacy of hydrolytic enzymes in surgery. Paper presented at: 24th FIMS World Congress of Sports Medicine; May 27-June 1, 1990; Amsterdam.
29. Vinzenz K. Treatment of edema with hydrolytic enzymes in oral surgical procedures [translated from German]. Quintessenz. 1991;42:1053-1064.
30. Seltzer AP. Minimizing post-operative edema and ecchymoses by the use of an oral enzyme preparation (bromelain): a controlled study of 53 rhinoplasty cases. Eye Ear Nose Throat Mon. 1962;41:813-817.
31. Blonstein JL. Control of swelling in boxing injuries. Practitioner. 1969;203:206. 26. Zatuchni GI, Colombi DJ. Bromelains therapy for the prevention of episiotomy pain. Obstet Gynecol. 1967;29:275-278.
32. Zatuchni GI, Colombi DJ. Bromelains therapy for the prevention of episiotomy pain. Obstet Gynecol. 1967;29:275-278.
33. Spaeth GL. The effect of bromelains on the inflammatory response caused by cataract extraction: a double-blind study. Eye Ear Nose Throat Mon. 1968;47:634-639.
34. Tassman GC, Zafran JN, Zayon GM. Evaluation of a plant proteolytic enzyme for the control of imflammation and pain. J Dent Med. 1964;19:73-77.
35. Howat RC, Lewis GD. The effect of bromelain therapy on episiotomy wounds-a double-blind controlled clinical trial. J Obstet Gynaecol Br Commonw. 1972;79:951-953.
36. Gylling U, Rintala A, Taipale S, et al. The effect of a proteolytic enzyme combinate (bromelain) on the postoperative oedema by oral application. A clinical and experimental study. Acta Chir Scand.1966;131:193-196.
37. Cameron IW. An investigation into some of the factors concerned in the surgical removal of the impacted lower wisdom tooth, including a double blind trial of chymoral. Br J Oral Surg. 1980;18:112-124.
38. Soule SD, Wasserman HC, Burstein R. Oral Proteolytic enzyme therapy (Chymoral) in episiotomy patients. Am J Obstet Gynecol. 1966;95:820-823.
40. Howat RC, Lewis GD. The effect of bromelain therapy on episiotomy wounds-a double blind controlled clinical trial. J Obstet Gynaecol Br Commow. 1972;79:951-953.
41. Frank SC. Use of chymoral as an anti-inflammatory agent following surgical trauma. J Am Podiatr Assoc.1965;55:706-709.
42. Gylling U, Rintala A, Taipale S, et al. The effect of a proteolytic enzyme combinate (bromelain) on the postoperative oedema by oral application. A clinical and experimental study. Acta Chir Scand.1966;131:193-196.
43. Tilscher H, Keusch R, Neumann K. Results of a double-blind, randomized comparative study of WobenzymW-placebo in patients with cervical syndrome [translated from German]. Wien Med Wochenschr .1996;146:91-95.
44. Singer F, Oberleitner H. Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus DiclofenacW [translated from German]. Wien Med Wochenschr . 1996;146:55-58.
45. Klein G, Kullich W. Reducing pain by oral enzyme therapy in rheumatic diseases [translated from German]. Wien Med Wochenschr . 1999;149:577-580.
46. Russell RM, Dutta SK, Oaks EV, et al. Impairment of folic acid absorption by oral pancreatic extracts. DigDis Sci. 1980;25:369-373.
47. Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf. 1997;17:342-356.
48. Layer P, Groger G. Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency. Digestion 1993;54(suppl 2):10-4.
49. Hingorani K. Oral enzyme therapy in severe back pain. Br J Clin Pract 1968;22:209-10.
50. Gaspardy G, Balint G, Mitsuova M, et al. Treatment of sciatica due to intervertebral disc herniation with Chymoral tablets. Rheum Phys Med 1971;11:14-9.
51. Stevens JC, Maguiness KM, Hollingsworth J, et al. Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy. J Pediatr Gastroenterol Nutr 1998;26:80-4.
52. Oades PJ, Bush A, Ong PS, Brereton RJ. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994;343:109 [letter].
53. Campbell CA, Forrest J, Muscgrove C. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994;343:109-10 [letter].
54. Milla CE, Wielinski CL, Warwick WJ. High-strength pancreatic enzymes. Lancet 1994;343:599 [letter].
55. Jones R, Franklin K, Spicer R, Berry J. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 1995;346:499-500 [letter].
56. Powell CJ. Pancreatic enzymes and fibrosing colonopathy. Lancet 1999;354:251 [letter].
57. Clinical Experience with Systemic Enzyme Therapy in the Treatment of Herpes zoster, Pospíilová A., Haklová L. II. dermato-venerology clinic, Faculty Hospital Brno-Bohunice Cesko-slovenská dermatologie, 1999, 74 (1), 17-20.
58. Possibility to Treat Herpes zoster Using Enzymes I. Mikazans Department of Dermatology, Medical Academy of Latvia, Riga, Latvia Australasian Journal of Dermatology 38 (2), 1997. Abstracts of the 19th World Congress of Dermatology, 15-20 June, 1997, Sydney, Australia
59. Introduction to Oral Enzyme Therapy and Its Use in Varicella zoster Treatment Kleine M.-W., Ertl D. Allergist, Egenhofenstrasse 18, 82152 Planegg/Munich, Germany Int J Tiss Reac XIX (1/2), 1997 - abstracts of 7th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, May 19-21, Geneva, Switzerland
60. Hydrolytic Enzymes in the Treatment of HIV Infections H. Jäger. Allgemeinmedizin (1990) 19: 160-164 Kuratorium für Immunschwäche, München.
61. Oral Enzyme Therapy in Hepatitis C patients Stauder G.,1 Kabil S.2. Int. J. Immunotherapy XIII(3/4) 153-158 (1997).
62. Clinical use of Belosorb and Wobenzym in the Treatment of Viral Hepatitis B Nikolaev V.G., Matiasch V.I., Kononenko V.V. Kiev, Ukraine. Presented at the conference "Current approaches in infectology, epidemiology, and microbiology", Kiev, 1998.
63. A Study of Serum Glycolytic Enzymes and Serum B Hepatitis in Relation to LIV.52 Therapy Patney NL, Pachori S. The Medicine and Surgery 1986;4:9
64. Stauder G, Kabil S. Oral enzyme therapy in hepatitis C patients. Int J Immunother 1997;3:153-158 Kabil S, Stauder G. Oral enzyme therapy in hepatitis C patients. Int J Tiss Reac 1997;1-2
65. Gonzalez NJ, Isaacs LL: Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 1999;33:117-24.
66. Leipner J, Saller R: Systemic enzyme therapy in oncology: effect and mode of action. Drugs. 2000;59:769-80.